精准肿瘤学时代复发胶质瘤重复手术以指导分子信息治疗的风险-获益分析
该回顾性研究分析了2017至2022年间70例因复发胶质瘤(WHO 2-4级)接受重复手术以获取组织进行分子靶向治疗的患者。结果显示,重复手术并发症率与初次或二次开颅术参照队列相比无显著差异,分子诊断产出率高,50%推荐靶向治疗、30%实际开始靶向治疗,重复手术后中位生存期全组399天,胶质母细胞瘤重复全切后348天。作者认为重复手术可在合理风险下提供分子诊断信息并辅助多模式治疗。
要点
- 重复手术并发症率与初次或二次开颅术参照队列相比无显著差异。
- 分子诊断产出率高,50%推荐靶向治疗、30%实际开始靶向治疗。
- 重复手术后中位生存期全组399天,胶质母细胞瘤重复全切后348天。
核心结论
- 复发胶质瘤手术可提供相关分子诊断信息,对靶向治疗有直接意义,术后并发症风险合理,术后生存满意,可补充多模式胶质瘤治疗。
研究设计与样本
- 回顾性分析2017至2022年因复发胶质瘤(WHO 2-4级)接受手术并以组织采样进行靶向治疗为目的的患者,将并发症率与本机构胶质瘤手术队列比较,并分析组织分子诊断产出、靶向治疗及术后生存率。
主要发现
- 2017至2022年间,为180例患者做出通过分子诊断进行靶向治疗的肿瘤委员会推荐,其中70例(38%)接受了重复手术。
- 诊断为IDH野生型胶质母细胞瘤48例(69%),其次为IDH突变型星形细胞瘤13例(19%)和少突胶质细胞瘤9例(13%)。
- 50例(71%)实现全切;64例(91%)组织进行下一代测序,58例(83%)进行DNA甲基化分析,24例(34%)进行mTOR磷酸化免疫组化。
- 35例(50%)推荐靶向治疗,21例(30%)开始靶向治疗。
- 术后7例(11%)需翻修手术,与本院初次开颅术参照队列的7%(p=0.519)和二次开颅术参照队列的6%(p=0.359)相比无显著差异;非缓解性神经功能恶化6例(10%),与初次开颅术后8%(p=0.612)和二次开颅术后4%(p=0.519)相比无显著差异。
临床怎么用
- 作者认为,复发胶质瘤手术可在合理术后并发症风险下提供相关分子诊断信息并对靶向治疗产生直接后果,且术后生存满意,因此可补充多模式胶质瘤治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surgery for recurrent glioma provides cytoreduction and tissue for molecularly informed treatment. With mostly heavily pretreated patients involved, it is unclear whether the benefits of repeat surgery outweigh its potential risks. METHODS: Patients receiving surgery for recurrent glioma WHO grade 2-4 with the goal of tissue sampling for targeted therapies were analyzed retrospectively. Complication rates (surgical, neurological) were compared to our institutional glioma surgery cohort. Tissue molecular diagnostic yield, targeted therapies and post-surgical survival rates were analyzed. RESULTS: Between 2017 and 2022, tumor board recommendation for targeted therapy through molecular diagnostics was made for 180 patients. Of these, 70 patients (38%) underwent repeat surgery. IDH-wildtype glioblastoma was diagnosed in 48 patients (69%), followed by IDH-mutant astrocytoma (n = 13; 19%) and oligodendroglioma (n = 9; 13%). Gross total resection (GTR) was achieved in 50 patients (71%). Tissue was processed for next-generation sequencing in 64 cases (91%), and for DNA methylation analysis in 58 cases (83%), while immunohistochemistry for mTOR phosphorylation was performed in 24 cases (34%). Targeted therapy was recommended in 35 (50%) and commenced in 21 (30%) cases. Postoperatively, 7 patients (11%) required revision surgery, compared to 7% (p = 0.519) and 6% (p = 0.359) of our reference cohorts of patients undergoing first and second craniotomy, respectively. Non-resolving neurological deterioration was documented in 6 cases (10% vs. 8%, p = 0.612, after first and 4%, p = 0.519, after second craniotomy). Median survival after repeat surgery was 399 days in all patients and 348 days in GBM patients after repeat GTR. CONCLUSION: Surgery for recurrent glioma provides relevant molecular diagnostic information with a direct consequence for targeted therapy under a reasonable risk of postoperative complications. With satisfactory postoperative survival it can therefore complement a multi-modal glioma therapy approach.
引用
- Alhalabi OT, Dao Trong P, Kaes M, et al. Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis. J Neurooncol. 2024. PMID: 38334907. doi:10.1007/s11060-024-04595-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。